Pediatric mechanical circulatory support - a review

Deborah Kozik1, Bahaaldin Alsoufi1

  • 1Department of Cardiovascular and Thoracic Surgery, Norton Children's Hospital, University of Louisville School of Medicine, Louisville, KY USA.

Insights

Pediatric mechanical circulatory support (MCS) faces challenges due to adult device size mismatches. Developing child-specific durable pumps is crucial as pediatric end-stage heart failure outpaces donor availability.

Area of Science:

  • Cardiovascular Surgery
  • Pediatric Cardiology
  • Biomedical Engineering

Background:

  • Mechanical circulatory support (MCS) history began in 1953 with heart-lung machines.
  • Adult end-stage heart failure has driven faster device development compared to pediatric applications.
  • Pediatric MCS has largely adapted adult devices, posing size-related challenges for smaller patients.

Purpose of the Study:

  • To review available mechanical circulatory support devices for pediatric patients.
  • To discuss support options for complex pediatric cases, including single-ventricle anatomy and biventricular support.
  • To highlight the growing need for pediatric-specific durable pumps due to donor organ scarcity.

Main Methods:

  • Review of existing literature and clinical data on pediatric mechanical circulatory support.
  • Discussion of device adaptations and challenges in the pediatric population.
  • Exploration of specialized support strategies for complex congenital heart defects.

Main Results:

  • Adult MCS devices are often ill-suited for pediatric patients due to anatomical size discrepancies.
  • A significant unmet need exists for durable, pediatric-appropriate MCS devices.
  • Complex cases require tailored approaches, including biventricular assist devices and total artificial hearts.

Conclusions:

  • Developing novel, size-appropriate durable mechanical circulatory support devices is critical for pediatric end-stage heart failure.
  • Ongoing research and trials, such as the Pumps for Kids, Infants, and Neonates (PumpKIN) Trial, are vital.
  • Registries like the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) are essential for tracking outcomes and advancing pediatric MCS.